View Older Stories View More Recent Stories

Aug 26, 2022 08:16AM Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
Aug 26, 2022 08:16AM Esperion Announces Bempedoic Acid (NEXLETOL®) Recommended as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway
Aug 4, 2022 04:05PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 4, 2022 04:05PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 2, 2022 07:00AM Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
Aug 2, 2022 07:00AM Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
Jul 25, 2022 03:00PM Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
Jul 25, 2022 03:00PM Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management
Jul 12, 2022 08:00AM Esperion to Report Second Quarter 2022 Financial Results August 2, 2022
Jul 12, 2022 08:00AM Esperion to Report Second Quarter 2022 Financial Results August 2, 2022
Jun 3, 2022 12:30PM Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
Jun 3, 2022 12:30PM Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin
Jun 2, 2022 08:00AM Esperion to Participate in the 2022 Jefferies Global Healthcare Conference
Jun 2, 2022 08:00AM Esperion to Participate in the 2022 Jefferies Global Healthcare Conference
Jun 1, 2022 04:00PM Esperion Therapeutics (ESPR) Announces the Appointment of J. Martin Carroll to its Board of Directors
Jun 1, 2022 04:00PM Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
Jun 1, 2022 04:00PM Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors
May 31, 2022 08:00AM Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions
May 31, 2022 08:00AM Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions
May 17, 2022 08:00AM Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
May 17, 2022 08:00AM Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference
May 3, 2022 07:00AM Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
May 3, 2022 07:00AM Esperion Reports First Quarter 2022 Financial Results and Provides Company Update
May 2, 2022 08:01AM Esperion Therapeutics (ESPR) Reports Publication of CLEAR Harmony Open-Label Extension Study Data
May 2, 2022 08:00AM Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology
May 2, 2022 08:00AM Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology
Apr 29, 2022 05:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 29, 2022 05:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 29, 2022 10:00AM Esperion to Participate in Upcoming Bank of America Securities 2022 Healthcare Conference
Apr 29, 2022 10:00AM Esperion to Participate in Upcoming Bank of America Securities 2022 Healthcare Conference
Apr 28, 2022 04:00PM Esperion Therapeutics (ESPR) Appoints Stephen Rocamboli to its Board
Apr 28, 2022 04:00PM Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
Apr 28, 2022 04:00PM Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors
Apr 25, 2022 08:00AM Esperion Supports Collaborative Study with an Integrated and Learning Health Care Delivery System in Northern California to Study the Effects of NEXLIZET® (bempedoic acid and ezetimibe) in Reducing L
Apr 25, 2022 08:00AM Esperion Supports Collaborative Study with an Integrated and Learning Health Care Delivery System in Northern California to Study the Effects of NEXLIZET® (bempedoic acid and ezetimibe) in Reducing L
Apr 19, 2022 07:00AM Esperion to Report First Quarter 2022 Financial Results May 3, 2022
Apr 19, 2022 07:00AM Esperion to Report First Quarter 2022 Financial Results May 3, 2022
Apr 13, 2022 08:01AM Esperion Therapeutics (ESPR) Announces Publication of Phase 3 Data for Bempedoic Acid
Apr 13, 2022 08:00AM Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology
Apr 3, 2022 12:00PM Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo
Apr 3, 2022 12:00PM Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo
Mar 29, 2022 08:00AM Esperion to Participate in Upcoming 21st Annual Needham Virtual Healthcare Conference
Mar 29, 2022 08:00AM Esperion to Participate in Upcoming 21st Annual Needham Virtual Healthcare Conference
Feb 24, 2022 08:00AM Esperion to Participate in Upcoming Virtual Cowen 42nd Annual Healthcare Conference
Feb 24, 2022 08:00AM Esperion to Participate in Upcoming Virtual Cowen 42nd Annual Healthcare Conference
Feb 22, 2022 07:00AM Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
Feb 22, 2022 07:00AM Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
Feb 8, 2022 08:00AM Esperion to Report Fourth Quarter and Full Year 2021 Financial Results February 22, 2022
Feb 8, 2022 08:00AM Esperion to Report Fourth Quarter and Full Year 2021 Financial Results February 22, 2022
Jan 28, 2022 05:00PM Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
View More Recent Stories View Older Stories